Long-Term Results of the Atrial Septal Defect Occluder ASSURED Trial for Combined Pivotal/Continued Access Cohorts
JACC: Cardiovascular Interventions · 2024
DOI: 10.1016/j.jcin.2024.07.013 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Athar M Qureshi und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Lillie Frank Abercrombie Division of Cardiology, Texas Children's Hospital, Houston, Texas, USA; Department of Pediatrics, Baylor College of Medi…. Hauptthemen laut MEDLINE: Cardiac Catheterization, Heart Septal Defects, Atrial, Septal Occluder Device. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: W L Gore & Associates Inc.
Abstract (Originalsprache)
BACKGROUND: The GORE CARDIOFORM ASD Occluder (GCA, W. L. Gore & Associates) was approved in 2019 for ostium secundum atrial septal defect (ASD) closure. OBJECTIVES: This study sought to report the combined pivotal and continued access cohorts of the ASSURED (Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs) trial results through 36 months. METHODS: This prospective, multicenter, single-arm trial evaluated procedural and clinical outcomes of ASD closure with the GCA. The primary endpoints were 6-month closure success following device implantation and composite clinical success (deployment/retention of device, safety, and closure). Technical and procedure success, safety, clinically significant new arrhythmia (CSNA) secondary endpoints, and wire frame fracture (WFF, with fluoroscopy) at 6 and 36 months were evaluated. RESULTS: Of 569 patients (median age of 10.4 years and median weight of 35.0 kg) who underwent attempted secundum ASD closure, 526 were technical successes. The mean stop-flow ASD diameter was 17.6 ± 5.3 mm. All 478 patients with 6-month imaging achieved closure success. Composite clinical success at 6 and 36 months was achieved in 87.6% (468/534) and 84.0% (351/418) of patients, respectively. Technical failure occurred in 8.1% (43/548), 30-day device- or procedure-related serious adverse event in 3.9% (21/534), and 6-month device events in 2.8% (15/534) of patients. At 30 days, 21 of 569 patients (3.7%) had CSNA. At 6 months, 138 of 436 (31.7%) patients had WFFs and 105 of 185 (56.8%) at 36 months (without sequelae). CONCLUSIONS: In this large congenital ASD device trial, the GCA had acceptable results. WFFs, although common, did not result in any clinical sequelae. The unique features, size range, and safety profile expand the options for secundum ASD closure. (Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs [ASSURED]; NCT02985684).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Lillie Frank Abercrombie Division of Cardiology, Texas Children's Hospital, Houston, Texas, USA; Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. Electronic address: axquresh@texaschildrens…
- Columbia University of New York, New York, New York, USA.
- Children's Hospital of Colorado, Aurora, Colorado, USA.
- Atrium Health/Wake Forest University, Winston-Salem, North Carolina, USA.
- University of Utah, Salt Lake City, Utah, USA.
- Mount Sinai Medical Center, New York, New York, USA.
Förderung
- W L Gore & Associates Inc
Zitieren
APA
Qureshi, A. M., Sommer, R. J., Morgan, G., Paolillo, J. A., Gray, R. G., Love, B., Goldstein, B. H., Sugeng, L., Gillespie, M. J., & GORE ASSURED Clinical Trial Investigators (2024). Long-Term Results of the Atrial Septal Defect Occluder ASSURED Trial for Combined Pivotal/Continued Access Cohorts. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2024.07.013
Vancouver
Qureshi AM, Sommer RJ, Morgan G, Paolillo JA, Gray RG, Love B, et al. Long-Term Results of the Atrial Septal Defect Occluder ASSURED Trial for Combined Pivotal/Continued Access Cohorts. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2024.07.013
BibTeX
@article{Qureshi2024,
author = {Qureshi, Athar M and Sommer, Robert J and Morgan, Gareth and Paolillo, Joseph A and Gray, Robert G and Love, Barry and Goldstein, Bryan H and Sugeng, Lissa and Gillespie, Matthew J and GORE ASSURED Clinical Trial Investigators, GORE ASSURED Clinical Trial Investigators},
title = {Long-Term Results of the Atrial Septal Defect Occluder ASSURED Trial for Combined Pivotal/Continued Access Cohorts},
journal = {JACC: Cardiovascular Interventions},
year = {2024},
doi = {10.1016/j.jcin.2024.07.013}
}
EUVIMED